| Gene symbol | MUC16 | Synonyms | CA125 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.2 | dbXrefs | |
| Description | mucin 16, cell surface associated | ||||
| GTO ID | GTC3916 |
| Trial ID | NCT06469281 |
| Disease | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma | Fallopian Tube Cancer |
| Altered gene | MUC16 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | 27T51 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1a/1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| Year | 2024 |
| Country | United States |
| Company sponsor | Regeneron Pharmaceuticals |
| Other ID(s) | 27T51-01 |
| Cohort1: CAR-T | |||||
|
|||||
| Cohort2: CAR-T_Cemiplimab | |||||
|
|||||
| Cohort3: CAR-T_Cemiplimab_Bevacizumab | |||||
|
|||||